Published April 25, 2018 This content is archived.
Gordon L. Amidon, BS '67, will receive a SUNY honorary doctorate of science at the School of Pharmacy and Pharmaceutical Sciences’ commencement ceremony on May 19.
Amidon has been called a true visionary in the pharmaceutical sciences for his sophisticated research, most notably in the area of oral drug absorption.
A fellow of the American Association of Pharmaceutical Scientists, the American Pharmacists Association and the American Association for the Advancement of Science, Gordon L. Amidon has been called a true visionary in the pharmaceutical sciences for his sophisticated research, most notably in the area of oral drug absorption.
Amidon is credited with developing the Biopharmaceutical Classification System (BCS), recognized and utilized worldwide to differentiate drugs on the basis of their solubility and permeability. Amidon’s scientific achievements have greatly contributed to the pharmaceutical community’s overarching understanding of drug absorption and serve as guiding principles used by the U.S. Food and Drug Administration to determine generic drug bioequivalents.
In January 2018, Amidon was awarded the American Pharmacists Association Academy of Pharmaceutical Research and Science (APhA-APRS) Takeru Higuchi Research Prize, which recognizes the highest accomplishments in pharmaceutical sciences and is international in scope and stature.
Amidon’s academic roots in his field began at UB, where he earned a bachelor’s degree in pharmacy in 1967. During his time in Buffalo, he gained a passion for the study of pharmacokinetics, the convergence of pharmacy and mathematics.
For over 130 years, the University at Buffalo School of Pharmacy and Pharmaceutical Sciences has continually been a leader in the education of pharmacists and pharmaceutical scientists, renowned for innovation in clinical practice and research. The school is accredited by the American Council of Pharmaceutical Education (ACPE) and is the No. 1 ranked school of pharmacy in New York State and No. 22 in the United States by U.S. News & World Report.